Obesity affects between 15% and 40% of adults with Crohn’s disease, and a 2026 cohort study asked what happens to them on a GLP-1 drug [1]. It drew on 162 organizations, matched 9,766 pairs on more than thirty covariates, and followed them for one year and again for five.
The utilization results are substantial and consistent. Hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38–0.43), emergency visits 18.9% against 25.3% (RR 0.75, 95% CI 0.71–0.79), and both associations held at five years. These are the outcomes that show up on a bill as well as in a chart, which makes them worth more attention than they usually get beside the weight figures.
The study also reports one-year mortality at 0.7% against 4.2% (RR 0.17, 95% CI 0.13–0.22), and then tells you not to believe it. Its authors write that the mortality difference is unlikely to reflect a true causal effect and should be treated as hypothesis-generating, and that healthy-user bias cannot be excluded. This is the second paper in this library to publish a dramatic mortality number and disown it in the same breath; the first is covered in the authors do not believe their own hazard ratio, and the reasoning there applies here unchanged.
The TNF inhibitor result needs the same discipline. Use was 7.1% against 10.9% (RR 0.65, 95% CI 0.60–0.72), which reads like less need for biologic escalation — and the authors state plainly that it should not be read that way, because their database cannot distinguish starting a TNF inhibitor from continuing one. A lower rate of recorded use is not the same fact as a lower rate of disease progression.
The most informative number is the one that did not move. Corticosteroid use at one year was the same in both arms, RR 1.00 with a confidence interval of 0.96 to 1.03. If a healthy-user effect were driving everything, it should have dragged that outcome too. It did not, which is a point in the findings’ favor, and by five years steroid use was modestly lower at RR 0.91.
None of this makes a GLP-1 a Crohn’s treatment, and the paper does not claim it. What it supports is metabolic safety in a group whose disease is often cited as a reason for caution, with a call for prospective work. That caution is mostly about motility, and the evidence behind it is thinner than the warnings suggest — the gastroparesis signal is worth reading before assuming it settles the question. Anyone with inflammatory bowel disease weighing one of these drugs is in a conversation with a gastroenterologist, not an intake form — the same conclusion reached from a different direction in the ulcerative colitis evidence.